Pelthos Therapeutics
Manufacturing · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4020 Stirrup Creek Dr Ste 110, Durham, N...Phone Number
(919) 908-2400Website
www.pelthos.comRevenue
$27.7 MillionStock Symbol
PTHSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Pelthos Therapeutics
Pelthos Therapeutics (pelthos.com) is a Durham, North Carolinabased commercialstage biopharmaceutical company focused on dermatology and cutaneous infectious diseases, commercializing ZELSUVMI (berdazimer) topical gel for molluscum contagiosum and advancing additional nitricoxidebased therapeutic products using its proprietary NITRICIL drugdelivery platform.Explore more
Pelthos Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pelthos Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Pelthos Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Pelthos Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Pelthos Therapeutics
Check out if Pelthos Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Pelthos Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Pelthos Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Pelthos Therapeutics launches new products
Earning: See what the market has to say on Pelthos Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Pelthos Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Pelthos Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pelthos Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pelthos Therapeutics.
Pelthos Therapeutics financials insights
Gather financial insights about Pelthos Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$50.1M
2026
Debt
$50M
Pelthos Therapeutics Tech Stack
Most Recent Scoops
Person-Based
Earnings, Finance
Person-Based
Earnings, Finance
Earnings
Pelthos Therapeutics has reported SG&A expenses of $27.7 million for Q2 2026, representing a 31% increase from $21.1 million in Q1 2026, primarily driven by a $5.3 million one-time non-recurring sales-based milestone related to the Xeglyze MI license, with total cash basis SG&A excluding milestones, royalties, and severance of approximately $16.2 million for Q2 2026 compared to $16.7 million for Q1 2026.
Earnings, Sales, Finance
Earnings
Pelthos Therapeutics has reported a net loss of $23.4 million for Q2 2026, compared to a net loss of $25.1 million for Q1 2026 as amended, and an adjusted EBITDA of negative $5.7 million for Q2 2026, compared to negative $8.0 million for Q1 2026.
Earnings, Finance
Earnings
Earnings, Quality Assurance, Logistics / Supply Chain, Inventory Management, Finance
Pelthos Therapeutics News & Media
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
Company to hold a conference call at 8:30 a.m. ET Company to hold a conference call at 8:30 a.m. ETPelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of the close of business on August 4, 2026 are entitled to notice of and to vote at the 2026 Annual Meeting. The Company anticipates filing the Notice of AnnualPelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective when the US market opened on June 29 as part of the 2026 Russell indexes reconstitution.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Pelthos Therapeutics
Sign Up For FreeTo access detailed company insights
Pelthos Therapeutics (pelthos.com) is a Durham, North Carolinabased commercialstage biopharmaceutical company focused on dermatology and cutaneous infectious diseases, commercializing ZELSUVMI (berdazimer) topical gel for molluscum contagiosum and advancing additional nitricoxidebased therapeutic products using its proprietary NITRICIL drugdelivery... Read More
